April 13, 2017
PhRMA Chairman Joaquin Duato The Japanese government should maintain the so-called price maintenance premium for on-patent drugs so as to retain the predictability of its market and keep attracting foreign investments that will secure patient access to innovative medicines, PhRMA...read more